跳至主要内容
临床试验/NCT00756171
NCT00756171已完成2 期

Colesevelam Versus Placebo in Cholestatic Pruritus. A Double-blind, Placebo-controlled Study

Foundation for Liver Research3 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2008年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
38
试验地点
3
主要终点
40% reduction of pruritus according to visual analogue scores

研究概览

简要总结

38 patients with pruritus due to chronic cholestatic liver disease will be evaluated in an investigator initiated, multicenter, double-blind, placebo-controlled, 3-week study assessing the effects of colesevelam on pruritus. Colesevelam is an oral, non-absorbable bile-acid sequestrant much more potent than cholestyramine but free of adverse effects. It is registered as a lipid lowering agent. The intensity of symptoms will be scored by means of daily Visual Analogue Scales (VAS). Fatigue, quality of life and cutaneous scratch lesions will also be evaluated using quantitative instruments.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with pruritus as a result of a cholestatic disorder
  • age above 18 years
  • informed consent

排除标准

  • use of cholestyramine
  • pregnancy
  • inability to understand or speak Dutch language
  • malignancy/life expectancy <6 months

研究组 & 干预措施

1

Experimental

Verum; colesevelam

干预措施: colesevelam (Drug)

2

Placebo Comparator

placebo

干预措施: placebo (Drug)

结局指标

主要结局

40% reduction of pruritus according to visual analogue scores

时间窗: 3 weeks

次要结局

  • improvement in quality of life scores(3 weeks)
  • Reduction in pruritus score/scratch lesions(3 weeks)

研究者

发起方
Foundation for Liver Research
申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验